Posted by: transdomo | November 19, 2009

Epigenomics AG: First Blood Test for Colorectal Cancer Available in Germany

Epigenomics AG, a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic products for cancer, today announced that several German laboratories will start offering laboratory-developed colorectal cancer blood tests based on Epigenomics’ proprietary biomarker mSEPT9 on October 1st, 2009.

A blood test for colorectal cancer early detection that is easily integrated into an annual health check-up and does not require patient involvement is believed to be more acceptable to doctors and patients and has the potential to greatly increase the effectiveness of national screening programs. If tested positive in such an easy to use blood test, patients would be referred to a gastroenterologist for colonoscopy to confirm the diagnosis and initiate early treatment.

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics’ tests in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.
The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, U.S.A.

Epigenomics

© Flavia Westerwelle

TransDomo,LLC
Klaus Westerwelle
33 Market Point Drive
Greenville, SC 29607
Phone: 864.908.0690
Email: info@transdomo.com
Transdomo
Westerwelle


Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: